Steelhead Therapeutics
- Biotech or pharma, therapeutic R&D
Steelhead is a pre-clinical stage company founded on pioneering complement research from Dr. Feng Lin's Lab, with seed funding from Cleveland Clinic Ventures. The company focuses on developing highly potent nanobody/nanofly therapies for proximal targets in the complement system. The lead candidate targeting C2 is undergoing optimization and non-GLP animal model testing with a timeline targeting IND submission by Q4 2026.
Address
ClevelandOhio
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}